Li Xiumei, Song Lina, Zhang Haidong, Ji Xianqun, Song Ping, Liu Junjie, An Peng
Department of Oncology, Surgery and Radiology, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Xiangyang, 441000, China.
Department of Internal Medicine, Pathology and Epidemiology, Xiangyang Key Laboratory of Maternal-Fetal Medicine on Fetal Congenital Heart Disease, Xiangyang No. 1 People's Hospital, Hubei University of Medicine, Hubei, P.R.C, Xiangyang, Hubei Province, 441000, China.
World J Surg Oncol. 2025 Mar 28;23(1):104. doi: 10.1186/s12957-025-03760-y.
This study aimed to develop predictive models for postoperative recurrence and overall survival in patients with brain glioma (BG) by integrating preoperative contrast-enhanced MRI-derived delta habitat radiomics features with clinical characteristics.
In this retrospective study, preoperative contrast-enhanced MRI data and clinical records of 187 BG patients were analyzed. Patients were stratified into non-recurrence (n = 100) and recurrence (n = 87) cohorts based on postoperative outcomes. The dataset was randomly divided into training and test sets (7:3 ratio). Delta habitat radiomic features were extracted from intratumoral and peritumoral edema regions. A radiomic score (Radscore) was generated via LASSO regression with ten-fold cross-validation in the training cohort. Clinical variables (gender, IDH1 mutation, 1p19q co-deletion, MRI enhancement patterns) and radiomic features were compared between groups using χ² or Student's t-tests. Multivariate logistic regression models incorporating significant predictors were developed. Model performance was evaluated using AUC comparisons (DeLong test), decision curve analysis (clinical utility), and validated via XGBoost machine learning. Nomograms were constructed to visualize recurrence and survival predictions.
The training cohort revealed significant intergroup differences in gender, IDH1 mutation, 1p19q co-deletion, MRI enhancement patterns, and delta habitat radiomic scores (Radscore1/2, p < 0.05). The combined model (clinical + radiomic features) demonstrated superior predictive performance for recurrence [AUC 0.921 (95% CI 0.861-0.961), OR 0.023, sensitivity: 87.18%, specificity: 82.03%] compared to clinical-only [AUC 0.802 (0.745-0.833), OR 0.036] and radiomic-only [AUC 0.843 (0.769-0.900), OR 0.034] models (p < 0.05, DeLong test). Decision curve analysis confirmed greater clinical net benefit for the combined model. These findings were replicated in the test cohort. The survival nomogram incorporated IDH1 mutation status, gender, and Radscore1/2, with Kaplan-Meier analysis verifying their prognostic significance (p < 0.01).
Delta habitat radiomics derived from preoperative contrast-enhanced MRI may enhance the accuracy of postoperative recurrence and survival predictions in BG patients. The validated nomograms provide actionable tools for optimizing postoperative surveillance and personalized clinical decision-making.
本研究旨在通过整合术前对比增强MRI衍生的δ栖息地放射组学特征与临床特征,开发脑胶质瘤(BG)患者术后复发和总生存的预测模型。
在这项回顾性研究中,分析了187例BG患者的术前对比增强MRI数据和临床记录。根据术后结果将患者分为非复发组(n = 100)和复发组(n = 87)。数据集随机分为训练集和测试集(7:3比例)。从瘤内和瘤周水肿区域提取δ栖息地放射组学特征。在训练队列中通过LASSO回归和十折交叉验证生成放射组学评分(Radscore)。使用χ²检验或Student's t检验比较两组之间的临床变量(性别、IDH1突变、1p19q共缺失、MRI增强模式)和放射组学特征。构建纳入显著预测因子的多变量逻辑回归模型。使用AUC比较(DeLong检验)、决策曲线分析(临床效用)评估模型性能,并通过XGBoost机器学习进行验证。构建列线图以可视化复发和生存预测。
训练队列显示性别、IDH1突变、1p19q共缺失、MRI增强模式和δ栖息地放射组学评分(Radscore1/2)在组间存在显著差异(p < 0.05)。与仅临床模型[AUC 0.802(0.745 - 0.833),OR 0.036]和仅放射组学模型[AUC 0.843(0.769 - 0.900),OR 0.034]相比,联合模型(临床 + 放射组学特征)对复发具有更好的预测性能[AUC 0.921(95% CI 0.861 - 0.961),OR 0.023,敏感性:87.18%,特异性:82.03%](p < 0.05,DeLong检验)。决策曲线分析证实联合模型具有更大的临床净效益。这些结果在测试队列中得到重复。生存列线图纳入了IDH1突变状态、性别和Radscore1/2,Kaplan - Meier分析验证了它们的预后意义(p < 0.01)。
术前对比增强MRI衍生的δ栖息地放射组学可能提高BG患者术后复发和生存预测的准确性。经过验证的列线图为优化术后监测和个性化临床决策提供了可行的工具。